MERCINELLI, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 121
AS - Asia 67
EU - Europa 61
Continente sconosciuto - Info sul continente non disponibili 42
SA - Sud America 9
AF - Africa 1
Totale 301
Nazione #
US - Stati Uniti d'America 111
RU - Federazione Russa 46
CN - Cina 28
SG - Singapore 20
IT - Italia 9
BD - Bangladesh 6
VN - Vietnam 5
BR - Brasile 4
CA - Canada 4
CO - Colombia 3
ES - Italia 3
JP - Giappone 3
AR - Argentina 2
HK - Hong Kong 2
MX - Messico 2
CR - Costa Rica 1
DE - Germania 1
FR - Francia 1
GB - Regno Unito 1
GT - Guatemala 1
IN - India 1
IQ - Iraq 1
NI - Nicaragua 1
SN - Senegal 1
TR - Turchia 1
TT - Trinidad e Tobago 1
Totale 259
Città #
San Jose 29
Council Bluffs 21
Singapore 12
Beijing 10
Moscow 6
Santa Clara 6
Los Angeles 3
Ashburn 2
Bologna 2
Brooklyn 2
Corona 2
Dallas 2
Ho Chi Minh City 2
Hong Kong 2
Medellín 2
Mexico City 2
New York 2
Phoenix 2
Allentown 1
Arapongas 1
Aurora 1
Baltimore 1
Brampton 1
Buffalo 1
Cataguases 1
Charlotte 1
Columbus 1
Da Nang 1
Dakar 1
Denver 1
Erbil 1
Florence 1
Grand Junction 1
Guatemala City 1
Guelph 1
Hillsborough 1
Igualada 1
Jacksonville 1
Lansdowne 1
Loganville 1
London 1
Managua 1
Milwaukee 1
Minneapolis 1
Montemurlo 1
Naperville 1
Navsari 1
North Kansas City 1
Oldenburg 1
Orem 1
Phú Thọ 1
Phủ Lý 1
Pomona 1
Port of Spain 1
Queen Creek 1
Richmond 1
Rionegro 1
Rockford 1
Rome 1
Saint-Lazare 1
Salsipuedes 1
San José 1
San José de la Rinconada 1
Sesto San Giovanni 1
Shanghai 1
São Paulo 1
Tokyo 1
Toronto 1
Trabzon 1
Tucson 1
Upper Marlboro 1
Washington 1
West Palm Beach 1
Westminster 1
Xi'an 1
Totale 166
Nome #
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI 73
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer 45
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC) 29
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatinbased chemotherapy before radical cystectomy (RC) 18
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non–muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials 17
Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials 14
Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study 13
The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC) 10
Diagnostic and treatment delays in penile cancer: a call to improve awareness and referral 10
Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel 9
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer 8
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer 8
Corrigendum to “Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non–muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials”(European Urology, (2025), (S0302283825048778), 10.1016/j.eururo.2025.12.022) 8
Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report 8
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer 7
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study 7
Data from Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer 6
Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study 6
Re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer 3
PROTEUS Trial the Day After: Practice Changing or Premature Escalation? 2
Totale 301
Categoria #
all - tutte 1.647
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.647


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/2026186 0 0 0 0 17 9 4 13 52 34 30 27
2026/2027115 39 57 19 0 0 0 0 0 0 0 0 0
Totale 301